LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
To determine the mutation status of human telomerase reverse transcriptase gene (TERT) promoter region in hepatocellular carcinoma (HCC) from different geographical regions.
|
25574106 |
2015 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Here we identified the frequency of mutations in telomerase reverse transcriptase (TERT) promoter was 34% in non-clear cell HCC (NCCHCC, n = 259) and 26.3% in clear cell HCC (CCHCC, n = 57).
|
28460432 |
2017 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
The current study provided the characteristics of genetic aberrations in NAFLD-HCC and suggested that TERT promoter mutations and chromosome 8p loss mainly contribute to NAFLD-related liver carcinogenesis.
|
27511114 |
2016 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
K19<sup>+</sup> HCC had TERT promoter mutations less frequently than K19<sup>-</sup> HCC (31% versus 59%; P = 0.022), and lacked alterations in KRAS and IDH1.
|
31017316 |
2019 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, we demonstrate a substantial role for the rs2853669 in HCC with TERT promoter mutation, which suggests that the combination of the rs2853669 and the mutation indicate poor prognoses in liver cancer.
|
26575952 |
2016 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were highly frequent in glioblastoma (83.9%), urothelial carcinoma (64.5%), oligodendroglioma (70.0%), medulloblastoma (33.3%) and hepatocellular carcinoma (31.4%).
|
25843513 |
2015 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
These data show that TERT promoter mutation is the most frequent genetic alteration in hepatocellular carcinoma known at this time.
|
25267585 |
2014 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Here, we investigated the occurrence and implications of genetic alterations in the TERT promoter in hepatitis B viral hepatocellular carcinoma (B viral HCC).
|
29987895 |
2018 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
HCC cases associated to factors other than hepatitis viruses are also frequently mutated in TERT promoter (43.6%, 52.6% and 57.7% in USA, Asia and Europe, respectively).
|
28529542 |
2017 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
An identical CTNNB1 mutation was identified in the 1996 liver tumor together with a TERT promoter mutation showing that this hepatocellular carcinoma results from the malignant transformation of the initial β-catenin inflammatory adenoma.
|
27984126 |
2017 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were consistently identified in both HCC and CC components, supporting TERT alteration as an early event in CHC evolution.
|
30690729 |
2019 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Finally, integrative analysis of HCAs transformed to hepatocellular carcinoma revealed β-catenin mutation as an early alteration and TERT promoter mutations as associated with the last step of the adenoma-carcinoma transition.
|
24735922 |
2014 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Atypical hepatocellular neoplasm and hepatocellular carcinoma also demonstrated largely similar genomic profiles, but TERT promoter mutations were restricted to hepatocellular carcinoma (21%) and copy number alterations were more common in hepatocellular carcinoma (64 vs 31%).
|
31189995 |
2019 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Our study demonstrates the importance of CTNNB1 mutations and NFE2L2-KEAP1 pathway activation in HB development and defines loss of genomic stability and TERT promoter mutations as prominent characteristics of aggressive HB with HCC features.
|
25135868 |
2014 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Cyclin-driven HCC display a unique signature of structural rearrangements with hundreds of tandem duplications and templated insertions frequently activating TERT promoter.
|
30531861 |
2018 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were highly related to the step-wise hepatocarcinogenesis because mutations were identified in 6% of LGDNs, 19% of HGDNs, 61% of eHCCs, and 42% of small and progressed HCC.
|
25123086 |
2014 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Thirty percent of HCCs harbored TERT promoter mutations and there was a significant difference in rs2736098 and rs2736100 genotypes between wt and mutant TERT promoter-bearing HCC tumors (P = 0.007 and 0.018, respectively).
|
28416747 |
2017 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations (10.5%) and broad copy-number aberrations in chromosomes 1 and 8 (3-7%) were identified as trunk gatekeepers in DNs and were maintained in sHCCs.
|
28843658 |
2017 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion: TERT elevation by AR through integrated HBV and point mutation at the TERT promoter region was identified as a mechanism for the male dominance of HBV-related HCCs; telomerase and AR thus may be targets for intervention of HCC.
|
30070724 |
2019 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Detection of TERT promoter mutations in those with low levels of AFP may aid diagnosis of HCC with atypical presentation.
|
27056898 |
2016 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
In hepatitis B surface antigen (HBs Ag)-positive HCC without TERT promoter mutations, HBV integration into TERT locus was found in 47% patients and was mutually exclusive to TERT promoter mutations.
|
26553052 |
2016 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
Our results showed aberrant methylation of the UTSS region of the TERT promoter in HCC (mean=15.1) compared with the adjacent normal tissues (mean=6.1, P<0.00001).
|
25683523 |
2015 |
LOC110806263
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
In conclusion, mutations in TERT promoter and in CTNNB1 gene represent specific cancer signatures in the pathogenesis of viral related HCC and could be promising early biomarkers as well as targets for tailored therapies.
|
27276713 |
2016 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
These data demonstrated that TERT promoter mutation is a frequent event in HCC; however, telomere length, but not the presence of a TERT promoter mutation, might have potential value as a prognostic indicator of HCC.
|
28151853 |
2017 |
LOC110806263
|
Liver carcinoma
|
0.100 |
GeneticVariation |
BEFREE |
We assayed mutations in the TERT promoter region by Sanger sequencing and used next-generation sequencing to analyze the entire coding regions of 7 well-characterized HCC driver genes-based on shared or discordant mutations in these genes, we classified the HCCs in each patient as IM, MC, or indeterminate.
|
29180252 |
2018 |